Search by
Poster Number

1, 2, 3, 4,
5, 6, 7, 8,
9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73

Click on the Poster to View the Poster Page

Atopic Dermatitis

POSTER 14

INTEGUMENT-INFANT: A Phase 2, 4-Week Open-Label Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less than 2 Years Old...

POSTER 15

Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-free Interval in a...

POSTER 16

Real-World Insights on Systemic Treatments and Disease Control in Atopic Dermatitis: Patient Satisfaction and Recap of Atopic Eczema...

POSTER 17

Patients Maintain Stable Response with No or Minimal Fluctuations during 3 Years of Continuous Treatment with Lebrikizumab during...

POSTER 18

Long-term Efficacy and Safety of Lebrikizumab Is Maintained in Patients with Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years...

POSTER 19

Lebrikizumab Improves Atopic Dermatitis in Patients with Limited Skin Involvement and High Itch Shawn Kwatra, Thomas Werfel, Martin...

POSTER 20

Nemolizumab Long-Term Safety and Efficacy up to 104 Weeks in the ARCADIA Open-Label Extension Study in Adolescents and Adults with...

POSTER 21

Long-Term Safety and Disease Control of Ruxolitinib Cream in Children Aged 2 to 6 and 7 to 11 Years With Atopic Dermatitis: Results From...

POSTER 22

Real-World Effectiveness of Tralokinumab in Adults with Atopic Dermatitis: Interim Data on Improvements in Patients with Head and Neck...

POSTER 23

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab Matthias...

POSTER 24

Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for Up to 6...

POSTER 25

Treatment-Free Disease Control After Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, Tina Bhutani,...

POSTER 26

Combined Skin Clearance and Quality of Life Response in Patients With Moderate-to-Severe Atopic Dermatitis With and Without Prior...

POSTER 27

Impact of Baseline Disease Severity on the Long-Term Efficacy and Safety of Abrocitinib Treatment in Adolescent Patients With...

POSTER 28

Effect of Abrocitinib and Dupilumab on the Incidence of Conjunctivitis in Patients With Atopic Dermatitis: An Analysis of Abrocitinib...

POSTER 29

Maintenance of Optimal Response Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab Thomas Bieber, Eric L. Simpson,...

POSTER 30

Dupilumab Safety and Efficacy Up To 3 Years in Children Aged 6 Months to 11 Years with Atopic Dermatitis Amy S. Paller, Eric L. Simpson,...

POSTER 31

Dupilumab Monotherapy Prevents Flares and Provides Sustained Control of Atopic Dermatitis Over 1 Year Across Various Dose Regimens Eric...

POSTER 32

Sustained Disease Control Among Adults with Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 5-Year Follow-up Results From the...

POSTER 33

Dupilumab Treatment Reduces Medium- and High-Potency Topical Corticosteroid Usage in Pediatric Patients Aged 6 Months to 5 Years With...

Search by Poster Number

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73